IL207597A0 - Inhibitors of the chemokine reeptor cxcr3 - Google Patents

Inhibitors of the chemokine reeptor cxcr3

Info

Publication number
IL207597A0
IL207597A0 IL207597A IL20759710A IL207597A0 IL 207597 A0 IL207597 A0 IL 207597A0 IL 207597 A IL207597 A IL 207597A IL 20759710 A IL20759710 A IL 20759710A IL 207597 A0 IL207597 A0 IL 207597A0
Authority
IL
Israel
Prior art keywords
reeptor
cxcr3
chemokine
inhibitors
reeptor cxcr3
Prior art date
Application number
IL207597A
Other languages
English (en)
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of IL207597A0 publication Critical patent/IL207597A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/033—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL207597A 2008-02-19 2010-08-12 Inhibitors of the chemokine reeptor cxcr3 IL207597A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2973808P 2008-02-19 2008-02-19
PCT/US2009/034340 WO2009105435A1 (en) 2008-02-19 2009-02-18 Inhibitors of the chemokine receptor cxcr3

Publications (1)

Publication Number Publication Date
IL207597A0 true IL207597A0 (en) 2010-12-30

Family

ID=40527535

Family Applications (1)

Application Number Title Priority Date Filing Date
IL207597A IL207597A0 (en) 2008-02-19 2010-08-12 Inhibitors of the chemokine reeptor cxcr3

Country Status (25)

Country Link
US (1) US8268828B2 (enExample)
EP (1) EP2262784B1 (enExample)
JP (1) JP2011512412A (enExample)
KR (1) KR20100123835A (enExample)
CN (1) CN102007108A (enExample)
AR (1) AR070430A1 (enExample)
AU (1) AU2009215643A1 (enExample)
BR (1) BRPI0908815A2 (enExample)
CA (1) CA2715557A1 (enExample)
CL (1) CL2009000368A1 (enExample)
CO (1) CO6241113A2 (enExample)
CR (1) CR11604A (enExample)
DO (1) DOP2010000254A (enExample)
EC (1) ECSP10010409A (enExample)
IL (1) IL207597A0 (enExample)
MA (1) MA32191B1 (enExample)
MX (1) MX2010008397A (enExample)
NI (1) NI201000132A (enExample)
NZ (1) NZ587380A (enExample)
PE (1) PE20091576A1 (enExample)
RU (1) RU2010138577A (enExample)
SV (1) SV2010003648A (enExample)
TW (1) TW200948791A (enExample)
WO (1) WO2009105435A1 (enExample)
ZA (1) ZA201005314B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20091576A1 (es) 2008-02-19 2009-11-05 Sanofi Aventis DERIVADOS DE 3-(AMIDO O SULFAMIDO)-4-(4-AZINIL SUSTITUIDO)BENZAMIDA COMO INHIBIDORES DEL RECEPTOR DE QUIMIOQUINAS CxCR3
EP2424840B1 (en) 2009-04-27 2014-08-06 Boehringer Ingelheim International GmbH Cxcr3 receptor antagonists
WO2011084985A1 (en) * 2010-01-07 2011-07-14 Boehringer Ingelheim International Gmbh Cxcr3 receptor antagonists
KR101251788B1 (ko) 2010-12-06 2013-04-08 기아자동차주식회사 차량 연비 정보 단말표시 시스템 및 그 방법
CA2834199C (en) * 2011-07-18 2020-01-07 Merck Patent Gmbh Benzamides as allosteric modulators of the fsh receptor
EP2601950A1 (en) 2011-12-06 2013-06-12 Sanofi Cycloalkane carboxylic acid derivatives as CXCR3 receptor antagonists
US9409897B2 (en) * 2012-01-10 2016-08-09 Merck Patent Gmbh Benzamide derivatives as modulators of the follicle stimulating hormone
CA2861020C (en) 2012-02-02 2018-07-17 Actelion Pharmaceuticals Ltd 4-(benzoimidazol-2-yl)-thiazole compounds and related aza derivatives and their use as cxcr3 receptor modulators
EP2666769A1 (en) 2012-05-23 2013-11-27 Sanofi Substituted B-amino acid derivatives as CXCR3 receptor antagonist
ES2671323T3 (es) 2013-07-22 2018-06-06 Idorsia Pharmaceuticals Ltd Derivados 1¿(piperazin¿1¿il)¿2¿([1,2,4]triazol¿1¿il)¿etanona
AR099789A1 (es) 2014-03-24 2016-08-17 Actelion Pharmaceuticals Ltd Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina
EP3193600A4 (en) * 2014-09-10 2018-05-23 Epizyme, Inc. Smyd inhibitors
PL3245203T3 (pl) 2015-01-15 2019-05-31 Idorsia Pharmaceuticals Ltd Pochodne hydroksyalkilopiperazyny jako modulatory receptora cxcr3
AR103399A1 (es) 2015-01-15 2017-05-10 Actelion Pharmaceuticals Ltd Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3
WO2018183145A1 (en) * 2017-03-26 2018-10-04 Takeda Pharmaceutical Company Limited Piperidinyl- and piperazinyl-substituted heteroaromatic carboxamides as modulators of gpr6
CN115974766B (zh) * 2023-01-04 2025-05-16 中国药科大学 N-苄基-3-苯基酰胺类衍生物、包含其的药物组合物及其应用
CN116410159B (zh) * 2023-06-09 2023-08-22 济南国鼎医药科技有限公司 一种恩曲替尼中间体的制备方法及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2052541A5 (enExample) 1969-06-13 1971-04-09 Takeda Chemical Industries Ltd
US3840556A (en) 1971-05-28 1974-10-08 Lilly Co Eli Penicillin conversion by halogen electrophiles and anti-bacterials derived thereby
US6124319A (en) 1997-01-21 2000-09-26 Merck & Co., Inc. 3,3-disubstituted piperidines as modulators of chemokine receptor activity
US6469002B1 (en) 2001-04-19 2002-10-22 Millennium Pharmaceuticals, Inc. Imidazolidine compounds
US6794379B2 (en) 2001-06-06 2004-09-21 Tularik Inc. CXCR3 antagonists
GB0203994D0 (en) 2002-02-20 2002-04-03 Celltech R&D Ltd Chemical compounds
US20050272936A1 (en) 2002-06-03 2005-12-08 Axten Jeffrey M Imidazolium cxcr3 inhibitors
US6734659B1 (en) 2002-06-13 2004-05-11 Mykrolis Corporation Electronic interface for use with dual electrode capacitance diaphragm gauges
CN101146793A (zh) * 2005-02-16 2008-03-19 先灵公司 具有cxcr3拮抗剂活性的新的杂环取代了的吡啶或苯基化合物
JP2008530220A (ja) 2005-02-16 2008-08-07 シェーリング コーポレイション Ｃｘｃｒ３アンタゴニスト活性を有する、ピラジニルで置換されたピペラジン−ピペリジン
EP1856097B1 (en) 2005-02-16 2012-07-11 Schering Corporation Pyridyl and phenyl substituted piperazine-piperidines with cxcr3 antagonist activity
WO2007002742A1 (en) * 2005-06-28 2007-01-04 Pharmacopeia, Inc. Substituted [1,4]-diazepanes as cxcr3 antagonists and their use in the treatment of inflammatory disorders
US7781437B2 (en) 2005-10-11 2010-08-24 Schering Corporation Substituted heterocyclic compounds with CXCR3 antagonist activity
EP1957076A2 (en) 2005-11-29 2008-08-20 Merck & Co., Inc. Thiazole derivatives as cxcr3 receptor modulators
PE20071144A1 (es) 2006-03-21 2008-01-10 Schering Corp COMPUESTOS HETEROCICLICOS DE PIRIDINA SUSTITUIDA COMO ANTAGONISTAS DEL RECEPTOR 3 DE a-QUIMIOCINA (CXCR3)
KR20090043512A (ko) 2006-07-14 2009-05-06 쉐링 코포레이션 Ｃｘｃｒ3 길항제 활성을 갖는 헤테로사이클릭 치환된 피페라진 화합물
PE20091576A1 (es) 2008-02-19 2009-11-05 Sanofi Aventis DERIVADOS DE 3-(AMIDO O SULFAMIDO)-4-(4-AZINIL SUSTITUIDO)BENZAMIDA COMO INHIBIDORES DEL RECEPTOR DE QUIMIOQUINAS CxCR3

Also Published As

Publication number Publication date
JP2011512412A (ja) 2011-04-21
US8268828B2 (en) 2012-09-18
SV2010003648A (es) 2011-01-31
TW200948791A (en) 2009-12-01
NZ587380A (en) 2011-09-30
MA32191B1 (fr) 2011-04-01
MX2010008397A (es) 2010-08-23
US20100305088A1 (en) 2010-12-02
ECSP10010409A (es) 2010-09-30
CO6241113A2 (es) 2011-01-20
ZA201005314B (en) 2011-03-30
CR11604A (es) 2010-10-05
BRPI0908815A2 (pt) 2019-09-24
CA2715557A1 (en) 2009-08-27
EP2262784B1 (en) 2014-04-16
AU2009215643A1 (en) 2009-08-27
RU2010138577A (ru) 2012-03-27
KR20100123835A (ko) 2010-11-25
AR070430A1 (es) 2010-04-07
WO2009105435A1 (en) 2009-08-27
EP2262784A1 (en) 2010-12-22
NI201000132A (es) 2011-03-16
DOP2010000254A (es) 2010-08-31
PE20091576A1 (es) 2009-11-05
CL2009000368A1 (es) 2009-06-26
CN102007108A (zh) 2011-04-06

Similar Documents

Publication Publication Date Title
IL207597A0 (en) Inhibitors of the chemokine reeptor cxcr3
IL209729A0 (en) Novel phenylpyrazinones as kinase inhibitors
ZA201004942B (en) Ptrrolopyrazine kinase inhibitors
PL3604510T3 (pl) Antidota na inhibitory czynnika xa i sposoby ich stosowania
SI2299999T1 (sl) Stat3 inhibitorji
IL211018A0 (en) Novel inhibitors
IL200153A0 (en) Novel phosphodiesterase inhibitors
EP2496230A4 (en) INHIBITORS OF IRE-1 ALPHA
ZA200905371B (en) Novel phosphodiesterase Inhibitors
ZA201102837B (en) Phosphodiestarase inhibitors
IL212700A0 (en) Novel pyrazolone-derivatives and their use as pd4 inhibitors
GB0816125D0 (en) Novel inhibitors
GB201019387D0 (en) Inhibitors
GB0915927D0 (en) Novel inhibitors
GB0707499D0 (en) Novel inhibitors
GB0707488D0 (en) Novel inhibitors
GB0707493D0 (en) Novel inhibitors
GB0704589D0 (en) Novel inhibitors
GB0707498D0 (en) Novel inhibitors
GB0707497D0 (en) Novel inhibitors
GB0707495D0 (en) Novel inhibitors
GB0707632D0 (en) Novel inhibitors
GB0806919D0 (en) Polymerase inhibitors
GB0806915D0 (en) Polymerase inhibitors
GB0806920D0 (en) Polymerase inhibitors